Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KQ 2003

Next Previous
Drug Profile

KQ 2003

Alternative Names: KQ-2003

Latest Information Update: 26 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novatim Immune Therapeutics (Zhejiang)
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple myeloma; POEMS syndrome
  • Preclinical Lupus nephritis; Systemic lupus erythematosus

Most Recent Events

  • 07 Dec 2024 Efficacy, adverse event and pharmacokinetics data from the phase I/II trial in Multiple myeloma at the 66th American Society of Hematology Annual Meeting and Exposition 2024 (ASH-Hem-2024)
  • 31 Aug 2024 Phase-I/II clinical trials in POEMS syndrome (Treatment-experienced) in China (IV) (Novatim Immune Therapeutics (Zhejiang) pipeline, February 2025) (NCT06518876)
  • 02 Feb 2024 Preclinical trials in POEMS syndrome in China (Parenteral), prior to February 2024 (Novatim Immune Therapeutics pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top